Skip to content

Study · In vitro (cells) · 1993

8 results

Insulin-like growth factor binding protein-1 from Hep G2 cells is potently inhibited by the truncated IGF-I analogue des-(1-3) IGF-I.

Lindgren BF, Isaksson M, Stern I, Hall K

Acta endocrinologica1 Jan 1993Cited by 3 (Europe PMC)

PMID7680515 (opens in a new tab)DOI10.1530/acta.0.1280081 (opens in a new tab)PepBankPUB-07680515
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3) IGF-I inhibited medium IGFBP-1 more in EMEM without phenolred than with phenolred.

    In plain wordsIn cells, des-(1-3) IGF-I reduced IGFBP-1 more in medium without phenolred than with phenolred.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 inhibition by medium composition
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    EMEM with phenolred
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    10 ng/mlAs given in this study (human).

    Source sentences

    Summary
    A greater inhibition of immunoreactive IGFBP-1 was obtained with des-(1-3) IGF-I (10 ng/ml) in Hep G2 medium when incubated in Eagle's Modified Essential Medium (EMEM) without phenolred compared to EMEM with phenolred; EMEM without phenolred was chosen for further experiments.
  2. 02LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3)IGF-I reduced IGFBP-1 dose dependently, with maximal effect at 3-10 micrograms/l after 24 h.

    In plain wordsIn cells, des-(1-3)IGF-I reduced IGFBP-1 as the dose increased.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseDose-dependent IGFBP-1 suppression
    Study

    humann: not reported in source

    Hep G2 cells
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    3-10 micrograms/l · 24 hAs given in this study (human).

    Source sentences

    Summary
    Des-(1-3)IGF-I decreases dose dependently the concentration of IGFBP-1, with a maximal effect at 3-10 micrograms/l when incubated for 24 h
  3. 03LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3)IGF-I caused small but significant IGFBP-1 inhibition after 8 h.

    In plain wordsIn cells, des-(1-3)IGF-I slightly reduced IGFBP-1 after 8 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 suppression after 8 h
    Study

    humann: not reported in source

    Hep G2 cells
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    10 micrograms/l · 8 hAs given in this study (human).

    Source sentences

    Summary
    10 micrograms/l of des-(1-3)IGF-I caused a small but significant inhibition of IGFBP-1 after 8 h incubation
  4. 04LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3)IGF-I produced IGFBP-1 inhibition reported as 41% of controls after 14 h.

    In plain wordsIn cells, des-(1-3)IGF-I inhibited IGFBP-1 after 14 h compared with controls.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 suppression after 14 h
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    Control
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    10 micrograms/l · 14 hAs given in this study (human).

    Measurements

    Reported IGFBP-1 inhibition
    41 % of controls
    14 h

    Source sentences

    Summary
    10 micrograms/l of des-(1-3)IGF-I caused a small but significant inhibition of IGFBP-1 after 8 h incubation and this inhibition was 41% and 33% of controls after 14 and 19 h incubation.
  5. 05LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3)IGF-I produced IGFBP-1 inhibition reported as 33% of controls after 19 h.

    In plain wordsIn cells, des-(1-3)IGF-I inhibited IGFBP-1 after 19 h compared with controls.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 suppression after 19 h
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    Control
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    10 micrograms/l · 19 hAs given in this study (human).

    Measurements

    Reported IGFBP-1 inhibition
    33 % of controls
    19 h

    Source sentences

    Summary
    10 micrograms/l of des-(1-3)IGF-I caused a small but significant inhibition of IGFBP-1 after 8 h incubation and this inhibition was 41% and 33% of controls after 14 and 19 h incubation.
  6. 06LabIn vitro (cells)Mechanism

    In Hep G2 cultures, IGF-I had relative IGFBP-1 suppression potency of 0.41 compared with des-(1-3)IGF-I after 16 h.

    In plain wordsIn cells, des-(1-3)IGF-I suppressed IGFBP-1 more potently than IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIGFBP-1 suppression potency versus IGF-I
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated · 16 hAs given in this study (human).

    Measurements

    IGF-I relative potency
    0.41 relative potency
    versus des-(1-3)IGF-I at 16 h

    Source sentences

    Summary
    The relative potencies at 16 h of incubation of IGF-I and insulin in suppressing IGFBP-1 in comparison to des-(1-3)IGF-I were 0.41 (0.25-0.78) and 0.08 (0.01-0.26), respectively.
  7. 07LabIn vitro (cells)Mechanism

    In Hep G2 cultures, insulin had relative IGFBP-1 suppression potency of 0.08 compared with des-(1-3)IGF-I after 16 h.

    In plain wordsIn cells, des-(1-3)IGF-I suppressed IGFBP-1 more potently than insulin.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIGFBP-1 suppression potency versus insulin
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    Insulin
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated · 16 hAs given in this study (human).

    Measurements

    Insulin relative potency
    0.08 relative potency
    versus des-(1-3)IGF-I at 16 h

    Source sentences

    Summary
    The relative potencies at 16 h of incubation of IGF-I and insulin in suppressing IGFBP-1 in comparison to des-(1-3)IGF-I were 0.41 (0.25-0.78) and 0.08 (0.01-0.26), respectively.
  8. 08LabIn vitro (cells)Mechanism

    In Hep G2 cultures, des-(1-3)IGF-I reduced IGFBP-1 mRNA dose dependently to 30% of control after 4 h.

    In plain wordsIn cells, des-(1-3)IGF-I reduced IGFBP-1 mRNA to 30% of control after 4 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 mRNA suppression
    Study

    humann: not reported in source

    Hep G2 cells
    Comparator
    Control
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    0.1-10 micrograms/l · 4 hAs given in this study (human).

    Measurements

    IGFBP-1 mRNA
    30 % of control
    4 h

    Source sentences

    Summary
    A dose-dependent decrease of IGFBP-1 mRNA to 30% of control was observed after 4 h incubation with 0.1-10 micrograms/l des-(1-3)IGF-I.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.